Profile data is unavailable for this security.
About the company
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
- Revenue in INR (TTM)21.03bn
- Net income in INR3.17bn
- Incorporated1992
- Employees1.40k
- LocationMarksans Pharma Ltd21 Lotus Business Park, Off New Link Road,, Andheri (W)MUMBAI 400053IndiaIND
- Phone+91 2 240012000
- Fax+91 2 240012099
- Websitehttp://www.marksanspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Advanced Enzyme Technologies Ltd | 6.05bn | 1.37bn | 44.18bn | 338.00 | 32.18 | -- | 25.45 | 7.31 | 12.28 | 12.28 | 54.16 | -- | -- | -- | -- | 17,892,400.00 | -- | 11.87 | -- | 13.19 | 76.42 | 72.20 | 23.02 | 25.79 | -- | 59.04 | -- | 7.49 | 2.13 | 6.44 | -11.66 | 3.24 | 28.32 | 14.87 |
| Aarti Drugs Ltd | 26.51bn | 1.80bn | 46.39bn | 1.50k | 25.85 | -- | 20.10 | 1.75 | 19.52 | 19.52 | 287.30 | -- | -- | -- | -- | 17,673,360.00 | -- | 9.91 | -- | 16.40 | 32.25 | 22.33 | 6.81 | 8.23 | -- | 8.29 | -- | 5.53 | 9.14 | 16.56 | -18.89 | 15.11 | 17.20 | 31.95 |
| Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 46.50bn | 1.40k | 23.90 | -- | 17.58 | 2.54 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.23bn | -6.71m | 53.82bn | 1.03k | -- | -- | 50.61 | 4.79 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
| Orchid Pharma Ltd | 8.12bn | 1.25bn | 54.71bn | 838.00 | 37.85 | -- | 34.42 | 6.74 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
| Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 67.27bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
| F D C Ltd | 19.16bn | 2.90bn | 73.83bn | 6.37k | 25.73 | -- | 22.46 | 3.85 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 75.13bn | 1.40k | 23.52 | -- | 19.41 | 3.57 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 75.39bn | 407.00 | -- | -- | -- | 70.67 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Procter & Gamble Health Ltd | 12.37bn | 2.27bn | 81.50bn | 1.41k | 35.96 | 10.11 | 32.28 | 6.59 | 136.55 | 136.55 | 745.23 | 485.49 | 1.15 | 2.51 | 10.40 | 8,791,756.00 | 21.02 | -- | 27.67 | -- | 69.97 | -- | 18.32 | -- | 2.79 | 383.03 | 0.0132 | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Strides Pharma Science Ltd | 39.53bn | -1.52bn | 82.35bn | 2.85k | -- | -- | 139.21 | 2.08 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
| Wockhardt Ltd | 27.76bn | -5.01bn | 86.89bn | 2.74k | -- | -- | -- | 3.13 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
| Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 97.42bn | 1.57k | 30.73 | -- | 26.07 | 6.16 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 101.56bn | 1.82k | 21.60 | 4.35 | 19.37 | 4.45 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Granules India Ltd | 45.26bn | 3.95bn | 102.59bn | 3.65k | 25.94 | -- | 17.15 | 2.27 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
| Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 103.01bn | 777.00 | 23.66 | -- | 21.04 | 6.32 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
Data as of Apr 30 2024. Currency figures normalised to Marksans Pharma Ltd's reporting currency: Indian Rupee INR
6.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 Mar 2024 | 12.64m | 2.79% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024 | 5.79m | 1.28% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 4.79m | 1.06% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 2.75m | 0.61% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.69m | 0.37% |
| Gfund Management Co., Ltd.as of 31 Mar 2024 | 637.05k | 0.14% |
| Fiduciary Management, Inc.as of 29 Feb 2024 | 630.00k | 0.14% |
| WCM Investment Management LLCas of 29 Dec 2023 | 345.40k | 0.08% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 330.36k | 0.07% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 308.42k | 0.07% |
More ▼
Data from 31 Dec 2023 - 15 Apr 2024Source: FactSet Research Systems Inc.
